Cabozantinib: An evolving therapy for hepatocellular carcinoma

Area of Science:

• Hepatocellular Carcinoma (HCC) Research
• Oncology Drug Development
• Cancer Immunotherapy

Background:

• Hepatocellular carcinoma (HCC) incidence is increasing, posing a significant global health challenge.
• Advanced HCC treatment options have been limited, with sorafenib being a primary therapy for years.
• Recent advancements include tyrosine kinase inhibitors (TKIs) and immunotherapies for HCC management.

Purpose of the Study:

• To review the mechanism of action of cabozantinib in advanced HCC.
• To discuss the outcomes of the CELESTIAL trial for cabozantinib in HCC.
• To explore the potential of cabozantinib in combination with immunotherapy for HCC.

Main Methods:

• Review of pre-clinical data on cabozantinib's molecular targets (VEGFR, MET, TAM kinases).
• Analysis of the Phase 3 CELESTIAL trial data comparing cabozantinib to placebo in advanced HCC patients.
• Examination of ongoing clinical trials investigating cabozantinib in combination therapies.

Main Results:

• The CELESTIAL trial demonstrated improved progression-free and overall survival with cabozantinib versus placebo.
• Cabozantinib showed benefits across various patient subgroups, including age, etiology, and prior treatment duration.
• Cabozantinib has a manageable safety profile, with dose modifications allowing for continued treatment.

Conclusions:

• Cabozantinib is a validated treatment option for advanced HCC patients progressing on or after sorafenib.
• Cabozantinib's multi-targeted action and immunomodulatory effects support its role in HCC therapy.
• Future research should focus on cabozantinib combinations and identifying predictive biomarkers for patient selection.